Butirilkolinesteraza štiti štakore od inhalacijske izloženosti subletalnim dozama sarina by Jři Bajgar et al.
391Bajgar J, et al. PROTECTION AGAINST SARIN INHALATION EXPOSUREArh Hig Rada Toksikol 2006;57:391-395
Original Scientific Paper
EQUINE BUTYRYLCHOLINESTERASE PROTECTS 
RATS AGAINST INHALATION EXPOSURE TO 
SUBLETHAL SARIN CONCENTRATIONS
Jiři BAJGAR, Lucie BARTOŠOVA, Josef FUSEK, Daniel JUN, and Kamil KU A
Department of Toxicology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech 
Republic
Received in March 2006
Accepted in August 2006
Protection experiments were conducted using different doses of equine serum butyrylcholinesterase (Eq 
BuChE) as pretreatment in rats. Cholinesterase activities were determined in blood [whole blood, red blood 
cells (RBC) acetylcholinesterase (AChE), and plasma BuChE] before and after sarin inhalation exposure 
in untreated rats and those pretreated with Eq BuChE. Brain AChE activity was also determined in the 
frontal cortex, basal ganglia and pontomedullar areas following exposure. Dose-dependent increases in 
plasma BuChE activity and no changes in the RBC and brain AChE activities were demonstrated following 
i.p. injection of different amounts of Eq BuChE. Decreases in plasma BuChE activity and RBC and brain 
AChE activities were observed in control rats following sarin inhalation exposure. In rats pretreated with 
Eq BuChE this inhibition was lower than in control animals. These results demonstrate protective effects 
of Eq BuChE pretreatment in rats intoxicated with sublethal concentrations of sarin by inhalation.
KEY WORDS: acetylcholinesterase, basal ganglia, frontal cortex, plasma, pontomedullar area, red 
blood cells, whole blood
Highly toxic organophosphates (OP), including 
nerve agents, are compounds used in chemical 
warfare and in terrorist attacks, as was the case with 
sarin in Matsumoto city attack in 1994 and Tokyo 
subway one year later. Protection against the OP 
effects (prophylaxis and treatment) is therefore of 
prime importance (1, 2).
Prophylaxis against nerve agents can be based 
on different principles: protection of cholinesterases 
against inhibition caused by OP/nerve agents, use of 
ligands binding or hydrolysing the toxic agent before 
its penetration to the target sites (scavenger effects) 
and use of different drugs to protect organisms against 
toxic effects (1, 3, 4).
Bioscavengers are effective prophylactics against 
the toxic action of nerve agents. They are very useful 
in exposure to both low and high doses nerve agents. 
In nerve agent exposure scavenger action must be 
swift (because the action of nerve agents is very fast), 
irreversible (not allowing further exposure) and specific 
(reacting with toxic agent only).
The use of scavengers as prophylactics was 
tested many years ago (5). It is noteworthy that in our 
Department, in the early eighties, the use of unpurified 
acetylcholinesterase (AChE, EC 3.1.1.7) (rat brain 
homogenate) was used for the treatment of O-ethyl 
S-2-dimethylaminoethyl methyl phosphonothiolate 
(EDMM) poisoning. In experiments on rats poisoned 
with EDMM and treated using peritoneal dialysis with 
different dialysis fluids, the effect of dialysis with rat 
brain AChE was about one half of the effect of antidotal 
treatment (6). However, further development of this 
method was not possible.
Enzymes seem to be very promising as scavengers; 
they sequester nerve agents at the very beginning of 
the toxic action, before OPs reach their physiological 
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targets, and have no side effects (7-14). Among a variety 
of enzymes studied (12, 15-17), butyrylcholinesterase 
(BuChE, EC 3.1.1.8) has proven to be the most useful. 
The reaction between BuChE and an OP is very rapid, 
including nerve agents sarin, soman, and VX. BuChE 
has a long residence time in humans, and exerts 
minimal immune reaction. Thanks to these favourable 
features BuChE is isolated and its pharmacokinetic 
and pharmacodynamic properties studied (12, 13). 
The aim of this study was to analyse the effects 
of equine BuChE (Eq BuChE) pretreatment in rats 




Female Wistar rats (BioTest, Konarovice), weighing 
200 g to 220 g, were divided in groups of five animals 
each.
The efficacy of Eq BuChE in providing protection 
against low concentrations of sarin
Equine serum butyrylcholinesterase (Eq BuChE) 
was a kind gift from Dr B. P. Doctor, WRAIR, Silver 
Spring, Maryland, USA. Protection experiments 
were conducted using different doses of Eq BuChE 
as a pretreatment in rats. Cholinesterase activities 
were determined in blood [whole blood, red blood 
cell (RBC) AChE, and plasma BuChE] before and 
after sarin inhalation exposure of untreated rats and 
rats pretreated with Eq BuChE. Brain AChE activity 
was also determined in the frontal cortex (FC), 
pontomedullar area (PM) and basal ganglia (BG) of 
the brain following exposure.
Control group 1 (C) received saline (0.1 mL kg-1,
i.p.) and 30 min later, their blood was sampled from 
the tail vein (see Table 1, column “Before”). Then 
the animals were exposed to air (without sarin) in an 
inhalation chamber of our own construction (18) for 
60 min. Thirty minutes later the animals were killed by 
decapitation and the blood and brain were collected 
(see Table 1, column “After”).
In control group 2 (C.250) the animals were 
exposed 60 min to air in the inhalation chamber. 
Immediately after removal from the chamber their 
blood was sampled (see Table 1, column “Before”) and 
then the animals received 250 mU kg-1 Eq BuChE i.p. 
After 30 min the animals were killed and the blood and 
brain were collected (see Table 1, column “After”). 
Control group 3 (C.sa) received saline (0.1 mL kg-1,
i.p.) and 30 min later their blood was sampled from 
the tail vein (see Table 1, column “Before”). Then the 
animals were exposed to sarin vapours (2.6 g L-1)
for 60 min, and 30 min later, the animals were killed 
and the blood and brain were collected (see Table1, 
column “After”).
Experimental groups E.125+sa, E.250+sa, 
E.500+sa received EqBuChE in respective doses of 
125 mU kg-1, 250 mU kg-1 and 500 mU kg-1, i.p. and 
30 min later their blood was collected from the tail vein 
(see Table 1, column “Before”) and the animals were 
exposed to sarin vapours (2.6 g L-1). Thirty minutes 
later the animals were killed and their blood and brains 
collected (see Table 1, column “After”).
Cholinesterase determination
Cholinesterase activities were determined according 
to Ellman et al. (19) using acetyl- or butyrylthiocholine 
iodides (Lachema Brno) as substrates and 5,5’-
Table 1  Changes in cholinesterase activities in biological material of rats following sarin inhalation and pretreatment with Eq BuChE
Group
Whole blood RBC Plasma
FC PM BG
Before After Before After Before After
C 9.98±0.6 9.94±0.49 6.96±0.34 7.00±0.27 2.98±0.16 3.00±0.16 252±14 248±12 1018±80
C.250 10.00±0.66 12.38±0.56ab 7.00±0.19 7.04±0.13 2.94±0.11 4.22±0.16ab 245±10 246±14 1013±50
C.sa 9.94±0.51 6.26±0.32ab 6.94±0.73 4.24±0.17ab 2.98±0.16 1.94±0.15ab 128±19b 102±12bc 931±35
E.125+sa 10.92±0.36 8.88±0.56abc 7.02±0.13 5.44±0.11abc 3.84±0.18c 2.50±0.16abc 159±16bc 128±10bc 951±38
E.250+sa 12.4±0.56 10.06±0.30ac 7.00±0.2 6.02±0.13abc 4.56±0.3c 2.76±0.11ac 183±22bc 146±19bc 994±24
E.500+sa 14.06±0.24 10.32±0.35ac 7.02±0.24 6.72±0.30c 5.18±0.16c 3.00±0.16ac 208±19c 162±34bc 996±27
FC – frontal cortex, PM – pontomedullar area, BG – basal ganglia. Activities are expressed in nkat L-1 or nkat g-1 wet weight tissue. Values are 
expressed as means ±SEM per group of five rats. Each determination was made in triplicate. Values for groups C.250 After and E.250+sa Before 
– not statistically different 
a – different (p<0.05) between Before and After values
b – different (p<0.05) from control group C
c – different (p<0.05) from sarin group C.sa
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dithiobis-2-nitrobenzoic acid, DTNB (Koch-Light) 
as chromogene. During the assay, the final dilution 
of the material in cuvette was 1:200 and the final 
concentrations of substrates and DTNB were 10-4 mol 
L-1. In RBC, the 71 % of activity was that of AChE and 
21 % of BuChE  (20). The activity was expressed as 
nkat per litre or per gram of wet weight tissue, or as 
percent of control values.
Statistical evaluation
Differences between groups were tested using the 
Student’s t-test.
RESULTS AND DISCUSSION
The dose of sarin used in our experiments was 
lower than its LD50 value, which was determined to 
be 4.5 g L-1 for one-hour exposure (21). The signs 
of poisoning were mostly muscarinic (salivation). 
Some fasciculations but not convulsions were also 
registered. Dose-dependent increases in plasma 
BuChE activity and no changes in the RBC or whole 
blood AChE activities were demonstrated following 
i.p. injection of different amounts of Eq BuChE. 
No change in AChE activity in the brain parts was 
observed following administration of 250 mU kg-1.
Decreases in plasma BuChE activity, and RBC, whole 
blood and brain AChE activities were observed in 
control rats following sarin inhalation exposure. In rats 
pretreated with Eq BuChE, this inhibition was lower 
than in control animals.
The results are summarized in Table 1. These 
results also document the validity of determined 
values for the whole blood. It was expected that in 
control group, cholinesterases would not be affected 
(C Before, C After). Before the administration of Eq 
BuChE (C.250, Before), the activity should have been 
the same as determined in control group (C Before, C 
After). The activity before administration of sarin (C.sa, 
Before) can also be taken as control value. The results 
of pretreatment with Eq BuChE (E.250+sa, Before) 
in the same dose as with the control group (C.250, 
After) should also be comparable (Table 1). 
Our results show that administration of Eq BuChE 
does not affect AChE either in RBC or in the brain. 
However, cholinesterase activities in plasma or in the 
whole blood increased depending on the dose of Eq 
BuChE administered. The increase in plasma activity 
was expected. The increase in the whole blood could 
be caused by increased BuChE activity, because of 
percentual representation of these two enzymes in the 
whole blood (AChE: 71%, BuChE: 29%) (20).
We observed a decrease in cholinesterase activity 
in RBC, plasma, whole blood, and brain parts following 
sarin inhalation.
After pretreatment with Eq BuChE followed by 
exposure of rats to sarin inhalation, all cholinesterases 
determined in their blood decreased depending on the 
dose of Eq BuChE administered. A similar decrease 
was observed for AChE in the brain parts, however, 
with a relative resistance of AChE activity in the basal 
ganglia. This was also observed by Sevelova et al.
(21). The protective effect could be higher because 
it takes about ten hours to reach maximum activity 
following cholinesterase administration (12).
Our results confirm the protective effects of 
Eq BuChE pretreatment in rats poisoned with 
sublethal concentrations of sarin by inhalation. The 
protective effect was observed for brain and peripheral 
cholinesterases (whole blood, RBC, plasma). Our 
results have not yet found practical application, but 
work in that direction is in progress (22). 
CONCLUSIONS
-  Administration of EqBuChE does not affect AChE 
activity in the brain and RBC and increases plasma 
BuChE.
-  AChE and BuChE activities decreased following 
sarin inhalation.
-  In rats pretreated with EqBuChE, sarin inhalation 
exposure led to a decrease in all cholinesterases 
which depended on the dose of EqBuChE.
-  These results demonstrate the protective effects of 
EqBuChE not only in the blood, but also in different 
brain areas.
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Sažetak
BUTIRILKOLINESTERAZA ŠTITI ŠTAKORE OD INHALACIJSKE IZLOŽENOSTI SUBLETALNIM 
DOZAMA SARINA
U ovome su radu na štakorima istražene mogu nosti profilakse butirilikolinesterazom iz konjskog seruma 
(Eq BuChE) u razli itim dozama. Aktivnost kolinesteraza izmjerena je u krvi (punoj krvi, eritrocitima i plazmi) 
prije i nakon inhalacije sarina u štakora koji su prethodno primili Eq BuChE. Tako er je nakon izlaganja 
sarinu mjerena aktivnost acetilkolinesteraze u tkivu uzetom iz eonog režnja mozga štakora, bazalnih 
ganglija i pontomedularnog podru ja. Nakon primjene razli itih doza Eq BuChE utvr en je porast aktivnosti 
butirilkolinesteraze u plazmi koji je odgovarao dozi, ali nije bilo promjena u aktivnosti acetilkolinesteraze 
u eritrocitima i moždanom tkivu. U kontrolnih je štakora zamije en pad aktivnosti butirilkolinesteraze u 
plazmi te acetilkolinesteraze u eritrocitima i moždanom tkivu nakon njihova izlaganja sarinu inhalacijskim 
putem. U štakora koji su primili profilaksu Eq BuChE ova je inhibicija bila slabija. Rezultati istraživanja 
potvr uju zaštitna svojstva konjske butirilkolinesteraze kao profilakse pri otrovanju štakora subletalnim 
dozama sarina.
KLJU NE RIJE I: acetilkolinesteraza, bazalni gangliji, eoni režanj, eritrociti, mozak, plazma, 
pontomedularno podru je, puna krv
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